Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Schmidt Website

Laura S. Schmidt, Ph.D.

Selected Publications

1)  Schmidt LS, Linehan WM.
Editorial comment.
Urology. 83: 675.e5, 2014.
[Journal]
2)  Farley MN, Schmidt LS, Mester JL, Peña-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PL, Eng C, Linehan WM, Brugarolas J.
A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
Mol. Cancer Res. 11: 1061-71, 2013.
[Journal]
3)  Schmidt LS.
Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.
Fam. Cancer. 12: 357-64, 2013.
[Journal]
4)  Hasumi H, Baba M, Hasumi Y, Huang Y, Oh H, Hughes RM, Klein ME, Takikita S, Nagashima K, Schmidt LS, Linehan WM.
Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.
J. Natl. Cancer Inst. 104: 1750-64, 2012.
[Journal]
5)  Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, Yang Y, Wei MH, Pautler SE, Peterson J, Stolle CA, Zbar B, Merino MJ, Schmidt LS, Pinto PA, Srinivasan R, Pacak K, Linehan WM.
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.
J. Urol. 188: 2063-71, 2012.
[Journal]
6)  Baba M, Keller JR, Sun HW, Resch W, Kuchen S, Suh HC, Hasumi H, Hasumi Y, Kieffer-Kwon KR, Gonzalez CG, Hughes RM, Klein ME, Oh HF, Bible P, Southon E, Tessarollo L, Schmidt LS, Linehan WM, Casellas R.
The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development.
Blood. 120: 1254-61, 2012.
[Journal]
7)  Benhammou JN, Vocke CD, Santani A, Schmidt LS, Baba M, Seyama K, Wu X, Korolevich S, Nathanson KL, Stolle CA, Linehan WM.
Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome.
Genes Chromosomes Cancer. 50: 466-77, 2011.
[Journal]
8)  Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N.
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
PLoS Genet. 7: e1002312, 2011.
[Journal]
9)  Hong SB, Oh H, Valera VA, Baba M, Schmidt LS, Linehan WM.
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
PLoS ONE. 5: e15793, 2010.
[Journal]
10)  Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R.
Molecular diagnosis and therapy of kidney cancer.
Annu. Rev. Med. 61: 329-43, 2010.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/11/2014.